Business Description
CytoDyn Inc
NAICS : 325412
SIC : 2834
ISIN : US23283M1018
Description
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.85 | |||||
| Equity-to-Asset | -3.04 | |||||
| Debt-to-Equity | -0.34 | |||||
| Debt-to-EBITDA | -2.15 | |||||
| Interest Coverage | 1.66 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 38.5 | |||||
| 3-Year EPS without NRI Growth Rate | 48 | |||||
| 3-Year FCF Growth Rate | 62 | |||||
| 3-Year Book Growth Rate | -47.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.11 | |||||
| 9-Day RSI | 51.21 | |||||
| 14-Day RSI | 50.68 | |||||
| 6-1 Month Momentum % | -17.16 | |||||
| 12-1 Month Momentum % | -44.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | |||||
| Quick Ratio | 0.4 | |||||
| Cash Ratio | 0.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 | |||||
| Shareholder Yield % | -1.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -133.96 | |||||
| ROIC % | 26.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 29.38 | |||||
| PEG Ratio | 1.15 | |||||
| EV-to-EBIT | -10.69 | |||||
| EV-to-EBITDA | -10.71 | |||||
| EV-to-FCF | -142.7 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.08 | |||||
| Earnings Yield (Greenblatt) % | -9.36 | |||||
| FCF Yield % | -0.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CytoDyn Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.009 | ||
| Beta | 1.09 | ||
| Volatility % | 79.13 | ||
| 14-Day RSI | 50.68 | ||
| 14-Day ATR (€) | 0.009036 | ||
| 20-Day SMA (€) | 0.11705 | ||
| 12-1 Month Momentum % | -44.5 | ||
| 52-Week Range (€) | 0.1 - 0.282 | ||
| Shares Outstanding (Mil) | 1,219.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CytoDyn Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CytoDyn Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CytoDyn Inc Frequently Asked Questions
What is CytoDyn Inc(STU:296)'s stock price today?
The current price of STU:296 is €0.12. The 52 week high of STU:296 is €0.28 and 52 week low is €0.10.
When is next earnings date of CytoDyn Inc(STU:296)?
The next earnings date of CytoDyn Inc(STU:296) is 2025-01-16 Est..
Does CytoDyn Inc(STU:296) pay dividends? If so, how much?
CytoDyn Inc(STU:296) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers